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Aspartate residues function as proton acceptors in catalysis and
are involved in ionic interactions stabilizing subunit assembly. In
an attempt to unravel the role of a conserved aspartate (D89) in
sheep-liver tetrameric serine hydroxymethyltransferase (SHMT),
it was converted into aspargine by site-directed mutagenesis. The
purified D89N mutant enzyme had a lower specific activity
compared with the wild-type enzyme. It was a mixture of dimers
and tetramers with the proportion of tetramers increasing with
an increase in the pyridoxal-5«-phosphate (PLP) concentration
used during purification. The D89N mutant tetramer was as
active as thewild-type enzyme andhad similar kinetic and spectral
properties in the presence of 500 lM PLP. The quinonoid
spectral intermediate commonly seen in the case of SHMT was
also seen in the case of D89N mutant tetramer, although the
amount of intermediate formed was lower. Although the purified
dimer exhibited visible absorbance at 425 nm, it had a negligible
visible CD spectrum at 425 nm and was only 5% active. The
INTRODUCTION
Serine hydroxymethyltransferase (EC 2.1.2.1) (SHMT), a
pyridoxal-5«-phosphate (PLP)-dependent enzyme, catalyses the
reversible conversion of serine and tetrahydrofolate (H
%
-folate)
into glycine and 5,10-methylene H
%
-folate [1]. This enzyme
catalyses the first step in the pathway for the interconversion of
folate co-enzymes and provides, almost exclusively (especially in
mammalian systems), one-carbon fragments for the biosynthesis
of a variety of end-products, such as DNA, RNA, ubiquinone,
methionine etc. [2,3]. The importance of SHMT in DNA synthesis
is reflected by the high levels of enzyme activity observed in
rapidly proliferating cells compared with resting cells [4]. SHMT
is a component of the thymidylate cycle along with dihydrofolate
reductase and thymidylate synthase [2]. These features point to
its potential as an alternate target for enzyme-directed cancer
chemotherapy [2,5,6].
SHMT from mammalian sources is a homotetramer with a
subunit molecular mass of C 53 kDa and 4 mol of PLP per mol
of enzyme [5–7], whereas the enzyme from prokaryotic sources
is a homodimer [8]. The crystal structure of human liver cytosolic
recombinant SHMT (hSHMT) showed that PLP is located at the
tight dimer interface, as in the case of other PLP-dependent
enzymes [6]. Alignment of SHMT sequences from a variety of
sources with other PLP-dependent enzymes showed that it
belongs to the group of fold type I PLP dependent enzymes [9].
Thus a comparative analysis of the properties of SHMT and its
mutants from eukaryotic and prokaryotic sources would help in
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recombinant SHMT; eSHMT, recombinant Escherichia coli SHMT; PLP, pyridoxal-5«-phosphate ; H4-folate, 5,6,7,8-tetrahydrofolate ; 2-ME, 2-
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apo-D89N mutant tetramer was a dimer unlike the apo-form of
the wild-type enzyme which was present predominantly as a
tetramer. Furthermore the apo mutant dimer could not be
reconstituted to the holo-form by the addition of excess PLP,
suggesting that dimer–dimer interactions are weak in this mutant.
The recently published crystal structure of human liver cytosolic
recombinant SHMT indicates that this residue (D90 in the
human enzyme) is located at the N-terminal end of the fourth
helix of one subunit and packs against K39 from the second N-
terminal helix of the other symmetry related subunit forming the
tight dimer. D89 is at the interface of tight dimers where the PLP
5«-phosphate is also bound. Mutation of D89 could lead to
weakened ionic interactions in the tight dimer interface, resulting
in decreased affinity of the enzyme for the cofactor.
Key words: pyridoxal-5«-phosphate, site-directed mutagenesis,
tetramer stability.
delineating the role of specific amino acids in catalysis, cofactor
binding and maintenance of oligomeric structure. Mutation of
K229 involved in forming a Schiff’s base with PLP in Escherichia
coli SHMT (eSHMT) [10] and of K256 in sheep liver cytosolic
recombinant SHMT (rSHMT) [11] showed that this residue was
essential for PLP binding and was not involved in proton
abstraction [10,11], unlike in other PLP enzymes [12–15]. In
addition, mutation of K256 leads to the dissociation of the
tetramer to dimers in the case of rSHMT [11]. Mutation of the
conserved histidine residue preceding the active-site lysine in
eSHMT showed that this residue was involved not in proton
abstraction but in reaction specificity [16]. Similarly, it was
shown in eSHMT that the conserved T226 plays an important
role in converting geminal diamine into the external aldimine
[17]. It was shown that R363 in eSHMT and the corresponding
residue R401 in rSHMT were essential for binding of substrate
carboxy group [18,19]. Mutation of the conserved H134, H147
and H150 in rSHMT established their roles in the maintenance
of oligomeric structure, cofactor binding and proton abstraction
respectively [20]. Furthermore, the N-terminal arm was shown to
be important for stabilizing the tetrameric structure of rSHMT
[21]. These results are in conformity with the recently determined
three-dimensional structure of hSHMT [6]. Asp-89 is a conserved
residue among all the 35 SHMT sequences reported thus far and
is located at the tight dimer interface [6]. We report, in this
communication, that mutation of this residue in rSHMT results
in the destabilization of the tetrameric enzyme and weakening of
cofactor binding, leading to a decrease in activity.
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EXPERIMENTAL
Materials
[a-$#P]dATP (300 Ci}mmol), l-[3-"%C]serine (55 mCi}mmol),
restriction endonucleases, Sequenase4 version 2.0 DNA
sequencing kit and T
%
DNA ligase were obtained from Amersham
International (Little Chalfont, Bucks., U.K.). Sephacryl S-200,
carboxymethyl (CM)-Sephadex, glycine l-serine, d-alanine, 2-
mercaptoethanol (2-ME), folic acid, PLP, isopropyl b-d-
thiogalactopyranoside and EDTA were obtained from Sigma
Chemical Co (St. Louis, MO, U.S.A.). Platinum oxide was from
Loba Chemie (Bombay, India). All other chemicals were
of analytical-reagent grade. The oligonucleotides, custom
synthesized, were purchased from Bangalore Genei Private Ltd
(Bangalore, India).
Bacterial strains, growth conditions and DNA manipulations
E. col strain DH 5a (Bethesda Research Labs., Bethesda, MD,
U.S.A.) was the recipient for all the plasmids used for DNA
isolations and subcloning. BL 21 (DE3) pLysS [22] strain was
used for the expression of rSHMT and D89N SHMT mutant
clones. Luria–Bertani medium or terrific broth with 50 lg}ml
ampicillin was used for growing E. coli cells containing the
plasmids [23]. Plasmids were prepared by the alkaline lysis
procedure described by Sambrook et al. [24]. The preparation of
competent cells and transformation were performed by the
method of Alexander [25]. The DNA fragments were eluted from
low-melting-point agarose gels after electrophoresis [24].
Site-directed mutagenesis
The D89N SHMT mutant was constructed by a PCR-based
megaprimer method [26,27]. The first PCR product (megaprimer)
was obtained using the mutant oligonucleotide (5«GAA-
TTCATCAATGAGCTAGAG 3«) and M13 (fi24) universal
reverse primer (5«GGAAACAGCTATGACCATG 3«). pUCSH
(pUC19 containing the SHMT cDNA fragment lacking 227 bp
at the 5« end) was used as a template. The full-length PCR
product was obtained using three primers, megaprimer (first
PCR product), SHP1 (5«TATGGCAGCTCCAGTCAAC 3«, at
the start of the gene) and the M13 (fi24) universal reverse
primer, using pETSH (containing a full-length cDNA for SHMT
[23]) as a template. The full-length PCR product, obtained after
two rounds of PCR, was subcloned into pUC19 at KpnI and
BamHI sites. This clone was digested with KpnI and PmacI
restriction enzymes to obtain the 520 bp fragment. The entire
520 bp fragment was sequenced using Sequenase4 version 2.0
DNA sequencing kit to confirm the mutation and to rule out the
presence of non-specific mutations. The 520 bp fragment con-
taining the mutated region was gel purified and swapped with the
wild-type clone, i.e. pETSH, and the mutation was reconfirmed
by sequencing of the expression construct.
Purification of wild-type and D89N SHMT
rSHMT (wild type) and D89N SHMT were overexpressed and
purified as described previously [19]. Briefly, the purification
procedure involved ammonium sulphate fractionation, CM-
Sephadex chromatography followed by gel-filtration using a
Sephacryl S-200 column. The wild-type and mutant enzymes
were purified under identical conditions in buffers containing
either 50 or 500 lM PLP. The final enzyme pellet was stored at
4 °C. When needed, the pellet was resuspended in buffer A
(50 mM potassium buffer, pH 7–4}1 mM 2-ME}1 mM EDTA)
dialysed against the same buffer. When the enzymes were purified
in the presence of 500 lM PLP, the pellet was dissolved in buffer
A containing 500 lM PLP and dialysed against the same buffer.
The dialysed enzyme was used for further studies. Protein was
estimated by measuring the absorbance at 280 nm, 1 absorbance
unit was equivalent to 1–2 mg}ml [20].
Enzyme assay
The enzyme activity was estimated as described earlier [28,29],
with minor modifications. Each 100 ll of assay mixture contained
400 mM potassium phosphate buffer, pH 7–4, with 1–8 mM
dithiothreitol, no added PLP or 50 lM or 500 lM PLP, 1–8 mM
H
%
-folate and an appropriate amount of the enzyme. The reaction
was started by the addition of 3–6 mM l-[3-"%C]serine
(100000 c.p.m.). After incubation for 15 min at 37 °C the reaction
was stopped by the addition of 100 ll of dimedone (400 mM in
50% ethanol). The reaction mixture was kept in a boiling-water
bath for 5 min and the H-"%CHO-dimedone adduct was extracted
into 3 ml of toluene. A 1 ml volume of toluene extract was added
to 5 ml of scintillation fluid (0–6% w}v 2,5-diphenyl oxazole in
toluene) and radioactivity was measured in a Rack Beta 1209
liquid-scintillation counter (LKB Wallac, Wallac Oy, Finland).
One unit of enzyme activity was defined as the amount of enzyme
that catalysed the formation of 1 lmol of formaldehyde per min
at 37 °C at pH 7–4. The specific activity was expressed as units
per mg of protein. For the determination of K
m
and k
cat
values,
the assay was carried out at various concentrations of serine
(0–4 mM) and the kinetic parameters were calculated by least-
squares fitting of the data on double-reciprocal plots.
Spectroscopy
The visible absorbance spectra were recorded at 25 °C in buffer
A containing 500 lM PLP in a Shimadzu UV–visible (UV-160)
spectrophotometer. The reference cuvette, when appropriate,
also contained 500 lM PLP in buffer A. PLP has a non-specific
absorbance at 425 nm. Therefore base-line correction was made
before the addition of the enzyme. CD measurements were
made with a Jasco-J-500A automated recording spectropolari-
meter. The CD spectra were recorded at room temperature
(25 °C) in buffer A containing 500 lM PLP, with the same buffer
as blank.
Preparation of the apo-enzyme
Apo-enzyme of SHMT was prepared as described previously
[29,30] with minor modifications. d-Alanine (200 mM) was added
to the holo-enzyme in 50 mM potassium phosphate buffer,
pH 7–4, containing 1 mM 2-ME, 1 mM EDTA and 200 mM am-
monium sulphate, and incubated at 37 °C for 4 h. The reaction
mixture was rapidly dialysed in a Centricon tube at 4 °C for 1 h
using buffer A not containing PLP. The pyruvate and
pyridoxamine phosphate (PMP) formed in the reaction were
removed by this procedure and the apo-enzyme had no
absorbance at 425 nm.
Thermal stability
Thermal denaturation of rSHMT and D89N SHMT was per-
formed in a Gilford Response II spectrophotometer from Ciba
Corning Diagnostics (Oberlin, OH, U.S.A.) as described by
Jagath et al. [21] with the following modifications. The protein
samples (300 ll, 0–3 mg}ml) in buffer A, either without or with
500 lM PLP, were heated from 30 to 80 °C at the rate of
1 °C}min. The absorbance change in each case was monitored at
287 nm. The first derivative of the thermal-denaturation profile,
obtained using the software supplied with the instrument, was
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used to evaluate the apparent transition temperature of both
proteins. The apparent denaturation temperature (apparent T
m
)
is defined as the temperature at which the value of the fraction of
the protein in the denatured state was 0–5. The thermal-denatur-
ation profiles of rSHMT and D89N SHMT in the presence of
serine in buffer A were similarly determined.
Size-exclusion chromatography
In order to determine the oligomeric status of the mutant, as well
as to separate dimer and tetramer forms of the mutant, a
calibrated TSK G 3000 SW gel-filtration column attached to
a Shimadzu LC 6A HPLC system was used. Buffer A (with
or without 500 lM PLP) was used as an eluent in this study.
RESULTS
Characterization of D89N SHMT
The visible CD spectra of rSHMT and D89N SHMT, purified
through an S-200 gel-filtration column, are shown in Figure
1 (curves a and b). It is apparent that the visible CD spectrum at
425 nm (characteristic of the presence of PLP Schiff’s base
attached to the active site) of D89N SHMT was approx. 50% of
the value for rSHMT. One possible reason for this could be the
loss of bound PLP during purification, as observed with other
mutations such as H134 and H147 [20]. It was therefore of
interest to compare the specific activities of the two enzymes
purified in the presence of 50 or 500 lM PLP. D89N SHMT had
a specific activity of 0–6 units}mg when purified in the presence
of 50 lM PLP and assayed in buffers not containing PLP. When
the concentration of PLP in the assay buffer was increased in the
range 0–500 lM PLP, a maximal value of 1–6 units}mg was
achieved at 50 lM and a higher concentration of PLP did not
either enhance or decrease the specific activity. However, when
D89N SHMT was purified in the presence of 500 lM PLP and
assayed in buffer containing 500 lM PLP, the specific activity
was 2–9 units}mg of protein. rSHMT, purified in the presence of
50 or 500 lM PLP, had a specific activity of 4 and 4–2 units}mg
respectively (Table 1). These results suggested that the higher
Figure 1 Visible CD spectra of rSHMT and tetramer and dimer of D89N
SHMT
rSHMT and the mutant enzyme (subunit concentration, 18–8 lM) in buffer A containing
500 lM PLP (at 25 °C) were use to record the CD spectra from 300–500 nm using a Jasco
J-500A automated recording spectropolarimeter. Curve a, rSHMT ; curve b, D89N SHMT (as
purified in the presence of 50 lM PLP, mixture of tetramer and dimer) ; curve c, D89N SHMT
(tetramer) ; curve d, D89N SHMT (dimer).
concentration of PLP (500 lM) is essential during the purification
of the D89N SHMT for obtaining maximal activity of the
enzyme; this was also reflected in the k
cat
and k
cat
}K
m
values
obtained from the corresponding double-reciprocal plots (Table
1).
Oligomeric status of D89N SHMT
The results presented in the previous section, as well as earlier
observations on rSHMT and its mutants [19–21], prompted a
more detailed examination of the oligomeric status of D89N
SHMT. The wild-type and mutant enzymes were purified in the
presence of 50 lM PLP as described in the Experimental section,
and the enzymes, after S-200 column chromatography, were
analysed on a calibrated HPLC TSK G-3000 column. rSHMT
was eluted as a single symmetrical peak with a retention volume
of 12–7 ml (Figure 2, curve a), corresponding to a molecular mass
of 220 kDa (tetramer). On the other hand, the D89N SHMT
mutant enzyme eluted as two peaks with retention volumes of
12–71 ml and 14–45 ml respectively, corresponding to tetrameric
and dimeric forms of SHMT (Figure 2, curve b). When D89N
SHMT was purified in an identical manner, but in the presence
of 500 lM PLP, and subjected to HPLC, it gave two peaks,
corresponding to tetrameric and dimeric forms (Figure 2, curve
c). However, the tetramer was present in a higher proportion
(70%) compared with the dimer (30%), suggesting that excess
PLP may be stabilizing the tetrameric structure of D89N SHMT.
Activity measurements
Results presented in Figure 2 indicate that D89N SHMT is
present as a mixture of tetramer and dimer. It was therefore of
interest to separate the tetramer and dimer and examine their
catalytic properties. The peak fractions corresponding to
tetramer and dimer were collected and concentrated by Centricon
(30 kDa cut-off) filtration. The concentrated samples were re-
chromatographed on a TSK G-3000 SW gel-filtration column
and were found to be homogeneous (Figure 2B inset : a, tetramer;
b, dimer). rSHMT was similarly processed and served as a
control. The specific activity of the purified D89N SHMT
tetramer in the absence of PLP in the assay buffer was 2–03
units}mg and it increased to 4–05 units}mg in the presence of
500 lM PLP. The dimer had a specific activity of 0–05 units}mg
and 0–2 units}mg in the absence and presence of 500 lM PLP
respectively. The dimeric form was only 5% as active as the wild-
type enzyme. It was of interest to calculate the specific activity of
the preparations, which contain dimers and tetramers in different
proportions (Figure 2, curves b and c). When the mutant enzyme
was purified in the presence of 50 lM PLP the tetramer and
dimer were in the proportions 30% and 70%, with a specific
activity of 1–6 units}mg; when the enzyme was purified in the
presence of 500 lM PLP the ratio was 70:30 with a specific
activity of 2–94 units}mg. The calculated specific activity of
1–6 units}mg and 2–94 units}mg corresponded to the amount
of tetramer present in the two preparations. The K
m
with respect
to serine and k
cat
for the D89N SHMT tetramer were similar
to those of rSHMT (Table 1). As the activity of the dimer was
very low and it was available in limited quantities, the kinetic
parameters could not be evaluated with confidence. The far-UV
CD spectra of tetrameric and dimeric D89N SHMT and rSHMT
indicated that mutation of the D89 residue did not result in any
significant change in the secondary structure of the protein
(results not shown).
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Table 1 Kinetic properties of rSHMT (wild type) and D89N SHMT
Specific activity
(units/mg)* Km (serine) (mM) kcat (s−
1) kcat/Km (s−
1 mM−1)
Enzyme None ›PLP None ›PLP None ›PLP None ›PLP
rSHMT 4–00 4–20 0–90 0–92 4–20 4–32 4–70 4–70
D89N SHMT
(purified in 50 lM PLP)
0–60 1–60 1–10 1–10 1–30 2–30 1–18 2–09
D89N SHMT
(purified in 500 lM PLP)
– 2–94 1–10 1–10 – 3–00 – 2–70
D89N SHMT
(tetramer)
2–03 4–05 1–10 1–10 2–13 3–90 1–19 3–50
* 1 unitfl 1 lmole of HCHO formed per min at 37 °C.
 Calculated per mole of subunit.
 None, enzyme purified using buffers containing 50 lM PLP and dialysed against buffer A without PLP and assayed in the absence of PLP.
 500 lM PLP added in the assay buffer.
Figure 2 Size-exclusion chromatography profiles of rSHMT and D89N
SHMT
(A) Wild-type and D89N SHMT enzymes (subunit concentration, 1–88 lM) after Sephacryl S-
200 gel-filtration chromatography were loaded on to a TSK-G 3000 size-exclusion chromato-
graphy column attached to a Shimadzu LC 6A HPLC instrument with an on-line UV detector
(SPD 6AV). The column was equilibrated with buffer A for curves a and b, and buffer A
containing 500 lM PLP was used to generate curve c. The flow rate was 1 ml/min. The column
was calibrated using standard protein molecular-mass markers. Curves a and b : rSHMT and
D89N SHMT respectively, purified in the presence of 50 lM PLP and dialysed against buffer
A not containing PLP. Curve c, D89N purified in the presence of excess PLP (500 lM) and
dialysed against buffer A containing 500 lM PLP. (B) (inset) purified tetramer and dimer of
D89N SHMT (1–88 lM) were re-chromatographed to check their purity. Curve a, tetramer ;
curve b, dimer.
Visible absorbance and CD spectra
D89N SHMT tetrameric (Figure 3A, curve b) and dimeric
(Figure 3A, curve c) forms isolated in the presence of 500 lM
PLP showed visible absorbance maxima at 425 nm in buffer A
containing 500 lM PLP, indicating the presence of an internal
aldimine in both cases as well as in rSHMT (Figure 3A, curve a).
When the dimer was dialysed against buffer A not containing
PLP, the internal aldimine spectrum disappeared (Figure 3A,
curve d), suggesting that the PLP was weakly bound. Similar
dialysis experiments did not cause any change in the spectrum of
rSHMT. However, dialysis of the D89N SHMT tetramer led to
Figure 3 Visible absorbance spectra of rSHMT, D89N SHMT (tetramer)
and D89N SHMT (dimer)
(A) Visible absorbance spectra of the proteins (subunit concentration, 9–4 lM) in buffer A
containing 500 lM PLP were recorded within a Shimazdu UV–visible spectrophotometer at
25 °C. The reference cuvette contained 500 lM PLP in buffer A. Curve a, rSHMT ; curve b,
D89N SHMT (tetramer) ; curve c, D89N SHMT (dimer). Curve d, D89N SHMT (dimer) dialysed
against buffer A not containing PLP. Curve e, enzyme preparation used in curve d›500 lM
PLP. (B) (inset) size-exclusion chromatography of D89N SHMT dimer on a TSK G-3000 column.
Curve a, D89N SHMT dimer dialysed against buffer A not containing PLP (——) and loaded
after pre-equilibration with buffer A. Curve b, D89N SHMT dimer after dialysis was reconstituted
with excess PLP (500 lM) in buffer A (----) and loaded after pre-equilibration with buffer A
containing 500 lM PLP. The protein concentration was 1–88 lM.
C 50% loss of absorbance at 425 nm, which was regained upon
the addition of 500 lM PLP (results not shown). Addition of
500 lM PLP to the dialysed dimer also restored the absorbance
at 425 nm (Figure 3A, curve e). As shown in Figure 1, curve a, the
PLP bound at the active site of rSHMT gives a characteristic CD
spectrum at 425 nm. The purified D89N SHMT tetramer also
gave a visible CD spectrum, similar to that of rSHMT (Figure 1,
curve c), whereas the dimer had a very negligible CD signal at
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Figure 4 Spectral intermediates in the reaction of D89N SHMT (tetramer)
and D89N SHMT (dimer) with glycine and H4-folate
The spectral intermediates formed upon addition of ligands to the enzyme (subunit concentration,
9–4 lM) was recorded in buffer A containing 500 lM PLP with a Shimadzu UV–visible
spectrophotometer at 25 °C from 350 nm to 550 nm. (A) D89N SHMT (tetramer) : curve a,
D89N SHMT (tetramer) enzyme only ; curve b, enzyme›200 mM glycine ; curve c,
enzyme›200 mM glycine›0–4 mM H4-folate. (B) D89N SHMT (dimer) : curve a, D89N
SHMT (dimer) enzyme only ; curve b, enzyme›200 mM glycine ; curve c, enzyme›200 mM
glycine›0–4 mM H4-folate.
425 nm (Figure 1, curve d). Dialysis of the D89N SHMT tetramer
against buffer not containing PLP resulted in the loss of CD
signal at 425 nm, which was regained upon the addition of PLP
(500 lM) (results not shown). On the other hand, the dialysed
dimer did not show a CD signal at 425 nm, even in the presence
of 500 lM PLP, although the absorbance at 425 nm was restored
(Figure 3, curve e). Furthermore, the oligomeric status of the
D89N SHMT dimer was unaltered even in the presence of
500 lM PLP (Figure 3B: a, in the absence of PLP; b, in the
presence of PLP).
Spectral intermediates
Whereas the D89N tetramer was fully active, the dimer had very
little activity. This required an examination of the intermediates
in the reaction to assess the effects of mutation on the enzyme. It
can be seen from Figure 4(A) that the addition of glycine to the
D89N SHMT tetrameric form of the enzyme (curve a) resulted
in a marginal decrease in absorbance at 425 nm (curve b), with
an indication of the formation of geminal diamine having
absorbance at 343 nm (results not shown). The addition of H
%
-
folate to the above mixture resulted in an increase in the
concentration of the quinonoid intermediate with absorbance at
495 nm (curve c). The molar absorption coefficient for the
quinonoid intermediate was calculated to be 29255 M−"[cm−" for
rSHMT (subunit concentration, 1 M) in the presence of 500 lM
PLP. The amount of intermediate formed in the case of the
D89N tetramer was calculated to be 0–48 lM}lM subunit using
this value. Thus, the concentration of the intermediate is 50% of
that observed for rSHMT. However, the k
cat
value for the D89N
mutant tetramer (3–9 s−") was similar to that of the wild-type
enzyme (4–32 s−"), suggesting that the mutation has probably not
significantly affected catalysis. When a similar experiment was
Figure 5 Gel-filtration profiles of rSHMT and D89N SHMT
Size-exclusion chromatography was performed by loading 1–88 lM enzyme on a TSK G3000
column as described in the legend of Figure 2. (A) Holo-enzymes of rSHMT (——) and D89N
SHMT tetramer (----). (B) Apo-enzymes of rSHMT (——) and D89N SHMT tetramer (----)
prepared by reaction with D-alanine. (C) Reconstituted rSHMT (——) and D89N SHMT
tetramer (----) with 500 lM PLP.
carried out with the D89N SHMT dimer, the addition of glycine
did not cause the expected decrease in absorbance at 425 nm, but
resulted in an increase in absorbance (Figure 4B, curve b). The
reasons for this increase is unclear. However, the addition of H
%
-
folate did not result in the expected increase in absorbance at
495 nm due to the formation of the quinonoid intermediate.
Thermal stability of mutant and wild-type enzymes
SHMT has been shown to undergo a change in conformation
from an open to a closed form upon addition of serine, which
results in an increase in the apparent T
m
value by 5–10 °C [31].
Though the D89N SHMT tetramer is catalytically as active as
rSHMT (Table 1), its apparent T
m
value (54 °C) was lower than
that of rSHMT (68 °C) in the presence of 500 lM PLP. The
addition of serine to the D89N tetramer and rSHMT markedly
increased the apparent T
m
values to 68 °C and 74 °C respectively.
There was no change in the apparent T
m
values of the dimer in
the presence or absence of serine, suggesting that serine probably
failed to interact with the dimer.
Removal of PLP from D89N SHMT and its reconstitution
It has been well established that PLP plays a crucial role in
maintaining the oligomeric structure of SHMT in addition to its
function in catalysis [32]. SHMT catalyses the transamination of
d-alanine to pyruvate and the bound PLP is converted into PMP,
which can be removed by dialysis or by Centricon filtration to
obtain the apo-enzyme. This reaction can be monitored by
measuring the increase in absorbance at 325 nm due to the
formation of PMP or by the decrease in absorbance at 425 nm
due to disruption of the PLP Schiff’s base at the active site. The
rate constants, for reaction with d-alanine, monitored by the
decrease in absorbance at 425 nm at 25 °C, were 0–31 min−" and
0–18 min−" for D89N SHMT tetramer and rSHMT respectively.
When PLP from the D89N SHMT tetramer (Figure 5A, broken
line) was removed by transamination with d-alanine, as described
in the Experimental section, it was eluted at a position cor-
responding to the dimeric form of SHMT (Figure 5B, broken
line), whereas rSHMT was eluted predominantly as a tetramer
with a small amount of dimer (Figure 5B, solid line). Addition of
PLP had no effect on the oligomeric status of apo-D89N SHMT
mutant (Figure 5C, broken line), whereas the addition of PLP to
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apo-rSHMT led to conversion of even the small amounts of the
dimer into the tetrameric form (Figure 5C, solid line).
DISCUSSION
Aspartate residues in several enzymes function to stabilize protein
structure and are involved in interactions that lead to com-
munication between subunits in an oligomeric protein [33]. They
also function as proton acceptors and can bind to cofactors [34].
A comparison of primary sequences of SHMT isolated from a
number of sources revealed that D89 was conserved among all
the SHMTs, suggesting that it could have an important function
either in maintaining the oligomeric structure or in catalysis. The
recently published crystal structure of the tetrameric hSHMT [6]
indicates that this residue (D90 in hSHMT) is located at the N-
terminal end of the fourth helix and packs against K39 from the
second N-terminal helix of a symmetry related subunit. Results
presented in this paper demonstrate that mutation of D89 to N
could lead to a weakening of the forces stabilizing the tetrameric
structure, probably due to loss of this intersubunit ionic inter-
action. As the tetrameric structure is stabilized by additional
interactions, especially by binding of the cofactor [6,35,36], the
effect of the mutation can be partly overcome by increasing the
concentration of PLP during the purification and assay. Observ-
ations in support of this suggestion are discussed below.
It is evident from Figure 2 that D89N SHMT, as isolated, is a
mixture of tetramers and dimers, with the proportion of tetramer
increasing when purified in the presence of 500 lM PLP, whereas
rSHMT is purified as a tetramer at all concentrations of PLP
with no indication of dimeric species. This suggests that the
mutation of D89 affects the stability of the tetramer. The D89N
SHMT mutant enzyme, purified in the presence of 50 lM PLP
and assayed in the absence of PLP, was only 14% as active as
rSHMT (Table 1). However, when it was purified in the presence
of 500 lM PLP and assayed in the presence of 500 lM PLP, its
activity was increased to 70% of that of rSHMT. To resolve the
question of whether higher concentrations of PLP were required
for increasing the activity or for enhancing the stability of the
enzyme, the activity of D89N SHMT was measured at various
concentrations of PLP. It was found that 50 lM PLP was
sufficient for observing maximum activity (40%). This would
suggest that the mutant enzyme was probably saturated with
PLP in this concentration range. A comparison of the activities
of the separated tetramer and dimer would provide some clues to
the role of PLP in stabilizing the enzyme or in catalysis. It is
evident from the results (Table 1) that the D89N SHMT tetramer
(in the presence of 500 lM PLP)was as active as rSHMT, whereas
the dimer was only marginally (5%) active. The k
cat
and k
cat
}K
m
values of the D89N tetramer were comparable with those of
rSHMT in the presence of 500 lM PLP (Table 1). These results
suggest that a higher concentration of PLP was required both for
catalysis and for stabilizing the tetrameric structure of the mutant
enzyme. The orientation of PLP in the tetramer, as monitored by
visible CD (Figure 1b), indicated that it was in the correct
orientation for catalysis. The quinonoid spectral intermediate,
commonly seen in the equilibrium mixture of SHMT, glycine and
H
%
-folate, was shown to have an absorption coefficient of
50000 M−"[cm−" in the case of rabbit liver [37] and pig liver [38]
SHMTs. In the case of rSHMT the value was calculated to be
29255 M−"[cm−" in presence of 500 lM PLP. Based on this
value, the concentration of the quinonoid intermediate in the
D89N mutant tetramer was found to be 0–48 lM. This would
suggest that the step subsequent to formation of the quinonoid
intermediate is probably faster in the case of the mutant, although
this may not be the rate-limiting step as the k
cat
values for the
mutant tetramer andwild-type enzymes are similar in the presence
of 500 lM PLP. It is therefore evident that the mutation has
probably not affected catalysis. The dimer was also capable of
binding PLP in the correct stoichiometric amount (Figure 3c),
but there was no significant visible CD signal (Figure 1d),
suggesting that the PLP is probably not in the proper con-
figuration. In situations where the dimer and tetramer were
present (Figure 2), the activity of the mixture correlated very well
with the concentration of the tetramer (Table 1).
Additional evidence in support of the suggestion that PLP
binding is affected by mutation is provided by the decreased
apparent T
m
for the mutant in the presence of 500 lM PLP and
serine, compared with rSHMT. In addition, the rate constant
for the removal of PLP from the active site by reaction with d-
alanine (0–31 min−") is higher than for rSHMT (0–18 min−").
More convincing evidence for the role of PLP and D89 in
maintaining the tetrameric structure was the observation that
upon removal of PLP, the D89N tetramer dissociated to a dimer,
whereas the rSHMT was present essentially as a tetramer. The
small amount of dimer present along with tetramer in the case of
apo-rSHMT was converted back into a fully active tetramer. On
the other hand, the dimer formed from the D89N SHMT
tetramer by removal of PLP could not be reconstituted upon the
addition of PLP, demonstrating the role of D89 in maintaining
the tetrameric structure of SHMT (Figure 5).
Although the molecular co-ordinates of the X-ray structure of
SHMT [6] are not yet in the public domain, based on the published
crystal structure of hSHMT it can be suggested that mutation of
D89 in sheep liver SHMT could lead to disruption of ionic
interaction with K38 from a symmetry related subunit, resulting
in weakening of tight dimer interactions and consequently
decreased affinity for PLP.
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